SPONSOR
Amgen
Total Trials
3
Recruiting
3
Phases
Phase 3, Phase 1
Amgen is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Non-Small Cell Lung Cancer (NSCLC), Obesity, Overweight, Diabetes Mellitus, Type 2.
The trial portfolio spans Phase 3, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Amgen
How many clinical trials has Amgen sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Amgen, of which 3 are actively recruiting participants. These trials cover conditions including Non-Small Cell Lung Cancer (NSCLC), Obesity, Overweight. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Amgen research focus on?
Amgen clinical trials span Non-Small Cell Lung Cancer (NSCLC), Obesity, Overweight, Diabetes Mellitus, Type 2. The research pipeline includes Phase 3, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Amgen clinical trial?
To participate in a Amgen trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Amgen trials with current recruitment status updated daily.
Clinical Trials by Amgen
NCT05920356 Phase 3
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
NCT07684235 Phase 3
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Obesity
NCT07590193 Phase 1
Recruiting
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology